American Society for Parenteral and Enteral Nutrition

RATIONALE: This initiative is focused on building a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings. METHODS: In January 2016, the Global Leadership Initiative on Malnutrition (GLIM) was convened by several of the major global clinical nutrition societies. GLIM appointed a core leadership committee and a supporting working group with representatives bringing additional global diversity and expertise. Empirical consensus was reached through a series of face-to-face meetings, telephone conferences, and e-mail communications. RESULTS: A two-step approach for the malnutrition diagnosis was selected, i.e., first screening to identify "at risk" status by the use of any validated screening tool, and second, assessment for diagnosis and grading the severity of malnutrition. The malnutrition criteria for consideration were retrieved from existing approaches for screening and assessment. Potential criteria were subjected to a ballot among the GLIM core and supporting working group members. The top five ranked criteria included three phenotypic criteria (weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present. Phenotypic metrics for grading severity as Stage 1 (moderate) and Stage 2 (severe) malnutrition are proposed. It is recommended that the etiologic criteria be used to guide intervention and anticipated outcomes. The recommended approach supports classification of malnutrition into four etiology-related diagnosis categories. CONCLUSION: A consensus scheme for diagnosing malnutrition in adults in clinical settings on a global scale is proposed. Next steps are to secure further collaboration and endorsements from leading nutrition professional societies, to identify overlaps with syndromes like cachexia and sarcopenia, and to promote dissemination, validation studies, and feedback. The diagnostic construct should be re-considered every 3-5 years.

PRELIMINARY REMARKS (INTENT OF GUIDELINES) A.S.P.E.N. and SCCM are both nonprofit organizations composed of multidisciplinary healthcare professionals. The mission of A.S.P.E.N. is to improve patient care by advancing the science and practice of clinical nutrition and metabolism. The mission of SCCM is to secure the highest quality care for all critically ill and injured patients. Guideline Limitations: These A.S.P.E.N.−SCCM Clinical Guidelines are based on general conclusions of health professionals who, in developing such guidelines, have balanced potential benefits to be derived from a particular mode of medical therapy against certain risks inherent with such therapy. However, practice guidelines are not intended as absolute requirements. The use of these practice guidelines does not in any way project or guarantee any specific benefit in outcome or survival. The judgment of the healthcare professional based on individual circumstances of the patient must always take precedence over the recommendations in these guidelines. The guidelines offer basic recommendations that are supported by review and analysis of the current literature, other national and international guidelines, and a blend of expert opinion and clinical practicality. The population of critically ill patients in an intensive care unit (ICU) is not homogeneous. Many of the studies on which the guidelines are based are limited by sample size, patient heterogeneity, variability in disease severity, lack of baseline nutritional status, and insufficient statistical power for analysis. Periodic Guideline Review and Update: This particular report is an update and expansion of guidelines published by A.S.P.E.N. and SCCM in 2009 (1). Governing bodies of both A.S.P.E.N. and SCCM have mandated that these guidelines be updated every three to five years. The database of randomized controlled trials (RCTs) that served as the platform for the analysis of the literature was assembled in a joint “harmonization process” with the Canadian Clinical Guidelines group. Once completed, each group operated separately in their interpretation of the studies and derivation of guideline recommendations (2). The current A.S.P.E.N. and SCCM guidelines included in this paper were derived from data obtained via literature searches by the authors through December 31, 2013. Although the committee was aware of landmark studies published after this date, these data were not included in this manuscript. The process by which the literature was evaluated necessitated a common end date for the search review. Adding a last-minute landmark trial would have introduced bias unless a formalized literature search was re-conducted for all sections of the manuscript. Target Patient Population for Guideline: The target of these guidelines is intended to be the adult (≥ 18 years) critically ill patient expected to require a length of stay (LOS) greater than 2 or 3 days in a medical ICU (MICU) or surgical ICU (SICU). The current guidelines were expanded to include a number of additional subsets of patients who met the above criteria, but were not included in the previous 2009 guidelines. Specific patient populations addressed by these expanded and updated guidelines include organ failure (pulmonary, renal, and liver), acute pancreatitis, surgical subsets (trauma, traumatic brain injury [TBI], open abdomen [OA], and burns), sepsis, postoperative major surgery, chronic critically ill, and critically ill obese. These guidelines are directed toward generalized patient populations but, like any other management strategy in the ICU, nutrition therapy should be tailored to the individual patient. Target Audience: The intended use of these guidelines is for all healthcare providers involved in nutrition therapy of the critically ill, primarily physicians, nurses, dietitians, and pharmacists. Methodology: The authors compiled clinical questions reflecting key management issues in nutrition therapy. A committee of multidisciplinary experts in clinical nutrition composed of physicians, nurses, pharmacists, and dietitians was jointly convened by the two societies. Literature searches were then performed using key words (critically ill, critical care, intensive care, nutrition, enteral, parenteral, tube feeding, and those related to assigned topics such as pancreatitis, sepsis, etc.) to evaluate the quality of evidence supporting a response to those questions, which were then used to derive a subsequent treatment recommendation. The literature search included MEDLINE, PubMed, Cochrane Database of Systemic Reviews, the National Guidelines Clearing House and an Internet search using the Google search engine for scholarly articles through an end date of December 31, 2013 (including ePub publications). While preference was given to RCTs, other forms of resource material were used to support the response, including nonrandomized cohort trials, prospective observational studies, and retrospective case series. Use of publications was limited to full-text articles available in English on adult humans. For all included RCTs, two readers completed data abstraction forms (DAFs) examining the data and assessing the quality of the research methodology to produce a shared evaluation achieved by consensus for each study (example of DAF provided in the supplemental data, Supplemental Digital Content 1, https://links.lww.com/CCM/B571). DAFs were constructed only for RCTs. When the strongest available evidence was a published meta-analysis, the studies from the meta-analysis were used to determine the quality of the evidence and assessed by two evidence assessors. The data from included trials were entered into Review Manager 5.2 software to create forest plots aggregating the effect size for each intervention and outcome (3). The key forest plots supporting the recommendation are included throughout the text and in the supplement data (Supplemental Digital Content 1, https://links.lww.com/CCM/B571). No new forest plots were created when a meta-analysis was evaluated. Since release of the 2009 A.S.P.E.N. and SCCM Clinical Guidelines, the concepts of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group have A of the methodology published The data from the Review Manager analysis was to software the of evidence for a given intervention and outcome was evaluated for created each that was then by a The are provided in the supplement data (Supplemental Digital Content 1, https://links.lww.com/CCM/B571). to the number of observational studies were critically but not to the However, in the observational studies were the only available evidence in a their quality of evidence was using When or observational study was available to a consensus of the group on the clinical practice was and the recommendation was on expert of recommendation for clinical practice was based on both the available evidence and the risks and benefits to patients. While each recommendation and provided the supporting a by the group and every committee was for their with the recommendation. of consensus was of authors with a particular recommendation. recommendation not this of with a consensus of other recommendations a of of or with all A.S.P.E.N. and SCCM clinical guidelines, this was to review by clinical experts from all the practice that would use the guidelines, both and to the A of the guidelines is in the supplement data (Supplemental Digital Content 1, https://links.lww.com/CCM/B571). A nutrition based on the guidelines on by the for the is in OF authors completed both an A.S.P.E.N. and SCCM of for and was or from were any any of the committee to the of nutrition by nutrition by therapy to of or and to as The of nutrition in the the be is with a in which patients a response with of organ and the three have in the of the and of in in the critically ill nutrition support in the critically ill population was as care to to and support the patient throughout the this strategy to nutrition in which the is to the response to and in the clinical of critical be achieved by and and nutrition support primarily by the is as a strategy that disease severity, in the ICU, and patient the use of a nutrition patients who benefit from nutrition on expert a of nutrition be performed on all patients to the ICU for is to be nutrition those patients to benefit from therapy. have with by critical that to of nutrition and However, in the critically ill always to international consensus group to the of of baseline nutrition have by A.S.P.E.N. and the of and the other nutrition is and by evaluation of baseline nutrition and of disease patients are to an nutrition of However, patients nutrition in an ICU require a nutrition Many and are used to evaluate nutrition status, such as the the the the and the However, only the and the determine both nutrition and disease Although both were based on retrospective have used to nutrition in in critically ill patients are by an 3 and those with a or a is not is available as a for the a nutrition prospective nonrandomized studies that patients nutrition are to benefit from with outcome and than patients nutrition While use and evidence is to date, in these their in the by as to the of and in the additional or when nutrition in critically ill adult on expert that nutritional include an evaluation of of the and of not using nutrition or as are not in critical the critical care the are a of the acute response in and of and not nutrition in the ICU are not in of nutrition or of nutrition therapy of and are and should not be used as is as a to and determine in in the ICU, given of use and A a of and is unless a for other is used to determine be to into nutrition and studies in ICU patients are of is in and are for use in critically ill and be of in the is the for in the critically ill adult that be used to determine when available and in the of that the of of on expert in the of that a published or a be used to determine requirements. for should determine in to the of nutrition therapy. be through published or The of be limited by and in the ICU that the and of include the of or supplemental and therapy and than have published in the literature, with from when to and as in an ICU are in and patients derived from patients are than derived from The of is related to in the critically ill such as and The only of using over other is However, in critically ill patients or in the of or should use or in these provided by and such as should be for when nutrition therapy to target as by to to nutrition While two that met data from that of and were provided in study patients to nutrition therapy was directed by issues with study a recommendation for use of a study of use of nutrition therapy the the of in therapy was directed by the and were but outcome were not evaluated A study in general ICU patients used both and to target by or a While the was than the obtained by only study patients were by an ICU were by of care ICU which to and in the study patients. The toward in study patients to is to in of their with to ICU and of by or by should be than and to and should be used be from in critically ill adult on expert an evaluation of of be the critical care to be the for supporting and For critically ill are than and are not met by of have a with to benefit from The to should be based on an of of be used to of by the of to that when studies are not available to are not for of and should not be used in the critical care in this is the benefit of in critically ill adult patients to or this that nutrition support therapy in the of be in the critically ill patient who is to of the of the by the and the release of as and by and supporting the of and that the and in to such as the and in from of is a that is of the major or The of the include of with for and greater of organ disease in are and the of is to outcome of organ and The specific for are to and the response, and disease of therapy include use of the as a for the of and use of as an for previous data from meta-analysis of trials by a toward when was to of after that A meta-analysis of trials by in and when was on of ICU A meta-analysis of trials by a in and but in organ failure when was of to the ICU, to after that an updated meta-analysis of that met the of all on with on of was with a in and to or nutrition nutrition a in outcome the use of or for adult critically ill the use of over in critically ill patients who require nutrition support therapy. of to the of critically ill patients is and to use of The of to are in a of patient populations in critical including major surgery, and acute While studies have a effect on the outcome effect from is a in and in patient and in and ICU previous to in with use of and were with use of to in of the by of the in the two of nutrition support therapy meta-analysis by a a of with use of to studies patients that met criteria, on which was to be with than ICU was with to by to and were not These in outcome from the of from studies and in the with in medical management and new nutrition nutrition the clinical evidence of to in critically ill adult on expert in the of and patient should be evaluated when of should not be to of The literature the that and evidence of or are not for of in the ICU in of on the and of ICU and postoperative are related to of the and of or etc.) and to in to of patients on are only of and not to or The for of the of is based on studies of which critically ill surgical the and of the of to the or greater disease and with have to have ICU than those with or ICU to with greater number of of days when to days with of of is with a greater number of of A greater number of of as is and clinical is the of of the for critically ill does the of of patient that the of be in the in those critically ill patients for or those who have to of to on expert consensus in critically ill is to in the therapy in the is and the to of The of of the of the tube is in the of the or or the the be by patient ICU and of and the to in critically ill in clinical including and of the data from the that met criteria, trials on with and trials a of to Although the of is in or and of is not via the benefit than nutritional of in adult critically ill on expert that in the of or should be the patient is of be with in patients of the of critical is provided to patients who are to sepsis, and and are for the is a with a retrospective review of patients of those patients of ICU and than those The effect of was in patients with When were for by for was with While be provided with to patients on of should be in patients who are in patients for are or in patients for are to For patients on therapy any of tube or of and should be as of and should be and OF population of patients in the ICU does not require nutrition support therapy over the of on expert that patients who are nutrition with baseline nutrition and disease 3 or who require nutrition therapy over the of in the to the ICU are a group with of nutrition and disease patients with nutrition baseline nutrition status, and disease by an of 3 or a are in the ICU for than a When these patients should be to to nutrition status, and organ Clinical trials of nutrition therapy in critically ill patients of patients with of the of that a lack of nutrition is in not and of in patients who potential of in the ICU patient population any benefit in the in However, patients and their nutrition and disease patients should be their disease severity, or expected the then of therapy. For which population of patients in the ICU is to over the of that or nutrition by is for patients with acute injury and those expected to have a of as these two of have patient over the of of randomized study of a population of patients with acute failure and randomized trial patients with and those expected to have a of of as or to for to days in a of over the of in the ICU than in clinical including and of to to based on The trial for of and the that study patients were critically ill and a in the ICU, nutrition is a lack of data available to determine the benefit of of those patients to be nutrition These patients were in the For these review population of patients in the ICU as to target nutrition in the of should target nutrition be in these on expert that patients who are nutrition or or should be toward as as over for to of or and should be in to the clinical benefit of over the of as or be to and in to but be insufficient to the for therapy in patients. that of be to in and in and to of in injury and to in patients a prospective nonrandomized that patients who nutrition therapy for in and to patients who insufficient therapy No were and insufficient in patients a observational for ICU patients with the of as of with in The was achieved with which provided For was and the of provided a in clinical of adult critically ill that should be are expected to be in the of and be in or patients sections and of studies in critical that of is to than of of the other of and the of by critically ill patients to be than A prospective observational study in patients that of both and was with a in in was when were met prospective observational study in a ICU, a in was with Group Group RCTs, in when a was provided of in the critical care with using Use of or to is of limited in the ICU OF should of be in the adult critically ill on expert that patients should be for of that of should be that a of for the patient the of or should be to of and to be by of and and of patient such as or is by of of and or that than of assessed by for as and than of patients their target their ICU A number of the of in the critical care providers who to only of requirements. of is This of and in patients on only of target from to the of in over of patients for an of of the for which are in of and of all While patient for a of only of this after for and of ICU patients and for to of issues the such as or the for to of patients randomized to surgical general than those patients for was for each be by and for which patients are be used as a for to ICU patients on that not be used as of care to ICU patients on for those are for in the of other of should be of not with of or Although a study that of over with using studies and three other trials using the of every to a trial using a and specific for a of were to be a for with a of a of and a of from that the for to of from a number of to a number of does not the of or the for does not the patient from these Use of to of of and of healthcare and outcome through of studies have that the practice of using of patient three trials, two and prospective trial with to of the trials greater by of or greater in trial but when were a trial in the practice of is a number of be used to critically ill patients on review of and evaluation of clinical for should be and to of should be sections and For those to using care should be in their in the of should and to the of to of but of should not for in the of other of be used in the adult ICU that be and to the of of to on expert that use of a or a be Use of or that and specific for of and or which be or have to be in the of provided in which or are of have to of nutrition These to to for is use the of of to and of individual as over the days of use in with and tube other with in patients who lack of the data from two studies that met use of to patient outcome by the of to was used of be assessed in critically ill patients and be to the of on expert that patients on should be assessed for of and that to of and should be is of the of for be by a number of including to the of a over of care, of the ICU, and use of and of the is with of than and of the of by in patients to be for of to the of of from the to the to the of and was in patients with including when to studies using evidence of to patients on was in ICU of or to on expert that for patients or those to be to of should be to The potential from of to of was in study a toward with to have greater with in of with but with to patient outcome in patients of to such as or be of Adding such as or to improve and of but in in clinical outcome for ICU patients. A of that met using and with were by No was in of or However, were with than with in three that met of have to a to be for to be in patients with For both and be with including and and should be used with including in the have with to therapy with and for greater were the of was in patients therapy clinical from therapy in of are this be Use of through the the of the of the in to improve was in study to the of and the of to and have to of after to date are studies their use as on expert that to of and be all ICU patients the of the should be and use of a should be the of the was in study to the of from to to health with was in two studies to and in patients While studies the use of in general ICU populations have outcome two studies in which care was included in in to would include the of when and of the ICU for and in in the critical care on expert that any be used as a for of on expert that not be used as for in the critical care for are use of a with other such as and have to and with an for was to be with and patient The and through a a against the use of as a for in patients on The basic for the use of in is related to of to be and use is by should with be assessed in the adult critically ill on expert that be for but that be the of in an ICU patient to determine in ICU patients is common but be as the from and in and to the with nutrition in and for the of in clinical the used are or of The to acute and of in of and in and including have an and and and as are and by with a of a in the patient is that have a effect on of are and of should include an of for evaluate for or and review of should be to from OF should be used when in the critically ill on expert using a when in the ICU the use of all in critically ill patients in a and in the For the of patients in an ICU a or to is and be This recommendation is of in that benefit to patient outcome in the literature for the use of in a general ICU including those that are to be disease specific organ specific (pulmonary, renal, or would be the use of an in the postoperative patient in a Use of outcome benefits over in a The for to to to be only with and their of and be used in a of patients on a to benefits such as and have an on clinical for the critically ill patient of the ICU with other including and should not be used in the for these should be for patients with and patients in the sections and of with and for the critically ill the must the patient is a for a While outcome benefits of and of with use of such in a general ICU medical and only a in to in a A meta-analysis of that met that to the have a in the critically ill but the data in the population not support any recommendation for use in of studies, studies, or studies, studies have addressed the individual their specific or their This of literature for the of studies, performed in a of ICU patient with a of and are as or but in their and of individual and are is not the data from published studies be to use of with that have not evaluated. on the of the populations and the in the the Guidelines that recommendation of support in the was with and be used in patients with or a recommendation this the use of an by an and in patients with and given of to have evaluated the use of or with an and in patients with and These studies have based on the of the used in the study by an of with study patients of to a in the for the effect of a in two of the studies all trials based on that use of and does not ICU of organ or to use of a this in of the data, the Guidelines that a with an in patients be used data are adult critically ill are the for or that a not be used in the adult critically ill patient to or of on expert use of a is evidence of both and in patients for or use of in the patient with with or lack of response to patients with other of have such as and benefit from use of a a or a supplement to a are both and of a available in a patient be in a critical care

BACKGROUND: This initiative aims to build a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings. METHODS: The Global Leadership Initiative on Malnutrition (GLIM) was convened by several of the major global clinical nutrition societies. Empirical consensus was reached through a series of face-to-face meetings, telephone conferences, and e-mail communications. RESULTS: A 2-step approach for the malnutrition diagnosis was selected, that is, first screening to identify at risk status by the use of any validated screening tool, and second, assessment for diagnosis and grading the severity of malnutrition. The malnutrition criteria for consideration were retrieved from existing approaches for screening and assessment. Potential criteria were subjected to a ballot among GLIM participants that selected 3 phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and 2 etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least 1 phenotypic criterion and 1 etiologic criterion should be present. Phenotypic metrics for grading severity are proposed. It is recommended that the etiologic criteria be used to guide intervention and anticipated outcomes. The recommended approach supports classification of malnutrition into four etiology-related diagnosis categories. CONCLUSIONS: A consensus scheme for diagnosing malnutrition in adults in clinical settings on a global scale is proposed. Next steps are to secure endorsements from leading nutrition professional societies, to identify overlaps with syndromes like cachexia and sarcopenia, and to promote dissemination, validation studies, and feedback. The construct should be re-considered every 3-5 years.

OBJECTIVES: Recent studies in animal models of sepsis-induced acute respiratory distress syndrome (ARDS) have shown that a low-carbohydrate, high-fat diet combining the anti-inflammatory and vasodilatory properties of eicosapentaenoic acid (EPA; fish oil), gamma-linolenic acid (GLA; borage oil) (EPA+GLA), and antioxidants improves lung microvascular permeability, oxygenation, and cardiopulmonary function and reduces proinflammatory eicosanoid synthesis and lung inflammation. These findings suggest that enteral nutrition with EPA+GLA and antioxidants may reduce pulmonary inflammation and may improve oxygenation and clinical outcomes in patients with ARDS. DESIGN: Prospective, multicentered, double-blind, randomized controlled trial. SETTING: Intensive care units of five academic and teaching hospitals in the United States. PATIENTS: We enrolled 146 patients with ARDS (as defined by the American-European Consensus Conference) caused by sepsis/pneumonia, trauma, or aspiration injury in the study. INTERVENTIONS: Patients meeting entry criteria were randomized and continuously tube-fed either EPA+GLA or an isonitrogenous, isocaloric standard diet at a minimum caloric delivery of 75% of basal energy expenditure x 1.3 for at least 4-7 days. MEASUREMENTS AND MAIN RESULTS: Arterial blood gases were measured, and ventilator settings were recorded at baseline and study days 4 and 7 to enable calculation of PaO2/FIO2, a measure of gas exchange. Pulmonary neutrophil recruitment was assessed by measuring the number of neutrophils and the total cell count in bronchoalveolar lavage fluid at the same time points. Clinical outcomes were recorded. Baseline characteristics of 98 evaluable patients revealed that key demographic, physiologic, and ventilatory variables were similar at entry between both groups. Multiple bronchoalveolar lavages revealed significant decreases (approximately 2.5-fold) in the number of total cells and neutrophils per mL of recovered lavage fluid during the study with EPA+GLA compared with patients fed the control diet. Significant improvements in oxygenation (PaO2/FIO2) from baseline to study days 4 and 7 with lower ventilation variables (FIO2, positive end-expiratory pressure, and minute ventilation) occurred in patients fed EPA+GLA compared with controls. Patients fed EPA+GLA required significantly fewer days of ventilatory support (11 vs. 16.3 days; p = .011), and had a decreased length of stay in the intensive care unit (12.8 vs. 17.5 days; p = .016) compared with controls. Only four of 51 (8%) patients fed EPA+GLA vs. 13 of 47 (28%) control patients developed a new organ failure during the study (p = .015). CONCLUSIONS: The beneficial effects of the EPA+GLA diet on pulmonary neutrophil recruitment, gas exchange, requirement for mechanical ventilation, length of intensive care unit stay, and the reduction of new organ failures suggest that this enteral nutrition formula would be a useful adjuvant therapy in the clinical management of patients with or at risk of developing ARDS.

Serum albumin and prealbumin, well-known visceral proteins, have traditionally been considered useful biochemical laboratory values in a nutrition assessment. However, recent literature disputes this contention. The aim of this document is to clarify that these proteins characterize inflammation rather than describe nutrition status or protein-energy malnutrition. Both critical illness and chronic illness are characterized by inflammation and, as such, hepatic reprioritization of protein synthesis occurs, resulting in lower serum concentrations of albumin and prealbumin. In addition, the redistribution of serum proteins occurs because of an increase in capillary permeability. There is an association between inflammation and malnutrition, however, not between malnutrition and visceral-protein levels. These proteins correlate well with patients' risk for adverse outcomes rather than with protein-energy malnutrition. Therefore, serum albumin and prealbumin should not serve as proxy measures of total body protein or total muscle mass and should not be used as nutrition markers. This paper has been approved by the American Society for Parenteral and Enteral Nutrition Board of Directors.

Enteral nutrition (EN) is a valuable clinical intervention for patients of all ages in a variety of care settings. Along with its many outcome benefits come the potential for adverse effects. These safety issues are the result of clinical complications and of process-related errors. The latter can occur at any step from patient assessment, prescribing, and order review, to product selection, labeling, and administration. To maximize the benefits of EN while minimizing adverse events requires that a systematic approach of care be in place. This includes open communication, standardization, and incorporation of best practices into the EN process. This document provides recommendations based on the available evidence and expert consensus for safe practices, across each step of the process, for all those involved in caring for patients receiving EN.

Martindale, Robert G. MD, PhD; McClave, Stephen A. MD; Vanek, Vincent W. MD; McCarthy, Mary RN, PhD; Roberts, Pamela MD; Taylor, Beth RD; Ochoa, Juan B. MD; Napolitano, Lena MD; Cresci, Gail RD American College of Critical Care Medicine the A.S.P.E.N. Board of Directors Author Information

The current era of healthcare delivery, with its focus on providing high-quality, affordable care, presents many challenges to hospital-based health professionals. The prevention and treatment of hospital malnutrition offer a tremendous opportunity to optimize the overall quality of patient care, improve clinical outcomes, and reduce costs. Unfortunately, malnutrition continues to go unrecognized and untreated in many hospitalized patients. This article represents a call to action from the interdisciplinary Alliance to Advance Patient Nutrition to highlight the critical role of nutrition intervention in clinical care and to suggest practical ways to promptly diagnose and treat malnourished patients and those at risk for malnutrition. We underscore the importance of an interdisciplinary approach to addressing malnutrition both in the hospital and in the acute posthospital phase. It is well recognized that malnutrition is associated with adverse clinical outcomes. Although data vary across studies, available evidence shows that early nutrition intervention can reduce complication rates, length of hospital stay, readmission rates, mortality, and cost of care. The key is to systematically identify patients who are malnourished or at risk and to promptly intervene. We present a novel care model to drive improvement, emphasizing the following 6 principles: (1) create an institutional culture where all stakeholders value nutrition, (2) redefine clinicians' roles to include nutrition care, (3) recognize and diagnose all malnourished patients and those at risk, (4) rapidly implement comprehensive nutrition interventions and continued monitoring, (5) communicate nutrition care plans, and (6) develop a comprehensive discharge nutrition care and education plan.

The prevalence of human oesophageal cytological abnormalities was determined by means of brush biopsy capsules in the adult occupants of each of 12 households in a low, an intermediate and a high oesophageal cancer rate area in Transkei during 1985 and 1986. Mild cellular changes (folic acid deficiency, atypia and mild dysplasia) as well as advanced changes (dysplasia and cancer) occurred more frequently in the occupants of households in high than in intermediate and low oesophageal cancer rate areas. The prevalence of fungi in homegrown maize from the households in each area was determined by plating surface-sterilized kernels on agar. The prevalence of Fusarium moniliforme was significantly higher (P less than 0.01) in maize from cytologically 'affected' households in the high oesophageal cancer rate area than from 'unaffected' households in the low oesophageal cancer rate area during both seasons. These results confirm previous reports on the difference in the prevalence of F. moniliforme in maize from low and high oesophageal cancer rate areas in Transkei. Whereas the previously established correlation was between F. moniliforme and oesophageal cancer rate, the present results provide evidence for an association between this fungus and oesophageal cytological abnormalities in living individuals. These people will be included in further clinical, epidemiological and aetiological studies.

Parenteral nutrition (PN) serves as an important therapeutic modality that is used in adults, children, and infants for a variety of indications. The appropriate use of this complex therapy aims to maximize clinical benefit while minimizing the potential risks for adverse events. Complications can occur as a result of the therapy and as the result of the PN process. These consensus recommendations are based on practices that are generally accepted to minimize errors with PN therapy, categorized in the areas of PN prescribing, order review and verification, compounding, and administration. These recommendations should be used in conjunction with other A.S.P.E.N. publications, and researchers should consider studying the questions brought forth in this document.

Malnutrition is common among hospitalized patients in the United States, and its coded prevalence is increasing. Malnutrition is known to be associated with increased morbidity, mortality and healthcare costs. Although national data indicate that the number of malnutrition diagnoses among hospital discharges has been steadily rising, an in-depth examination of the demographic and clinical characteristics of these patients has not been conducted. We examined data from the 2010 Healthcare Cost and Utilization Project (HCUP), the most recent nationally-representative data describing U.S. hospital discharges. Using ICD-9 codes, we constructed a composite variable indicating a diagnosis of malnutrition. Based on our definition, 3.2% of all U.S. hospital discharges in 2010 had this diagnosis. Relative to patients without a malnutrition diagnosis, those with the diagnosis were older, had longer lengths of stay and incurred higher costs. These patients were more likely to have 27 of 29 comorbidities assessed in HCUP. Finally, discharge to home care was twice as common among malnourished patients, and a discharge of death was more than 5 times as common among patients with a malnutrition diagnosis. Taken together, these nationally representative, cross-sectional data indicate that hospitalized patients discharged with a diagnosis of malnutrition are older and sicker and their inpatient care is more expensive than their counterparts without this diagnosis.

Parenteral nutrition (PN) represents one of the most notable achievements of modern medicine, serving as a therapeutic modality for all age groups across the healthcare continuum. PN offers a life-sustaining option when intestinal failure prevents adequate oral or enteral nutrition. However, providing nutrients by vein is an expensive form of nutrition support, and serious adverse events can occur. In an effort to provide clinical guidance regarding PN therapy, the Board of Directors of the American Society for Parenteral and Enteral Nutrition (ASPEN) convened a task force to develop consensus recommendations regarding appropriate PN use. The recommendations contained in this document aim to delineate appropriate PN use and promote clinical benefits while minimizing the risks associated with the therapy. These consensus recommendations build on previous ASPEN clinical guidelines and consensus recommendations for PN safety. They are intended to guide evidence-based decisions regarding appropriate PN use for organizations and individual professionals, including physicians, nurses, dietitians, pharmacists, and other clinicians involved in providing PN. They not only support decisions related to initiating and managing PN but also serve as a guide for developing quality monitoring tools for PN and for identifying areas for further research. Finally, the recommendations contained within the document are also designed to inform decisions made by additional stakeholders, such as policy makers and third-party payers, by providing current perspectives regarding the use of PN in a variety of healthcare settings.

BACKGROUND: Patients with lung cancer often experience reduced functional capacity and quality of life after surgery. The current study investigated the impact of a short-term, home-based, multimodal prehabilitation program on perioperative functional capacity in patients undergoing video-assisted thoracoscopic surgery (VATS) lobectomy for nonsmall cell lung cancer (NSCLC). METHODS: A randomized controlled trial was conducted with 73 patients. Patients in the prehabilitation group (n = 37) received a 2-week multimodal intervention program before surgery, including aerobic and resistance exercises, respiratory training, nutrition counseling with whey protein supplementation, and psychological guidance. Patients in the control group (n = 36) received the usual clinical care. The assessors were blinded to the patient allocation. The primary outcome was perioperative functional capacity measured as the 6-minute walk distance (6MWD), which was assessed at 1 day before and 30 days after surgery. A linear mixed-effects model was built to analyze the perioperative 6MWD. Other outcomes included lung function, disability and psychometric evaluations, length of stay (LOS), short-term recovery quality, postoperative complications, and mortality. RESULTS: The median duration of prehabilitation was 15 days. The average 6MWD was 60.9 m higher perioperatively in the prehabilitation group compared to the control group (95% confidence interval [CI], 32.4-89.5; P < .001). There were no differences in lung function, disability and psychological assessment, LOS, short-term recovery quality, postoperative complications, and mortality, except for forced vital capacity (FVC; 0.35 L higher in the prehabilitation group, 95% CI, 0.05-0.66; P = .021). CONCLUSIONS: A 2-week, home-based, multimodal prehabilitation program could produce clinically relevant improvements in perioperative functional capacity in patients undergoing VATS lobectomy for lung cancer.

Starting in October 2006 the Association of Surgeons of Great Britain and Ireland, the Society of Academic and Research Surgery, BAPEN Medical, the Intensive Care Society, the Association for Clinical Biochemistry and the Renal Association, nominated core members of a steering committee who came together to establish consensus for good peri-operative fluid prescribing. Concern arose regarding a high incidence of postoperative sodium and water overload, and evidence to suggest that preventing or treating this, by more accurate fluid therapy, would improve outcome. The following recommendations (28 in total) are extracted from the complete document which can be found on the ICS website ( http://www.ics.ac.uk/downloads/2008112340_GIFTASUP%20FINAL_31-10-08.pdf ). Members of the steering committee used the definitions of the Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001) accessed from http://www.cebm.net/index.aspx?o=1025 to assign levels of evidence, each of which, after debate, was accepted unanimously. However, debate is on-going and you are encouraged to have your say. Please communicate your thoughts on this published summary to the editor of JICS who will seek response from the authors.

Older adults are especially vulnerable to malnutrition, which often goes undetected and increases the risks of illness and death. The Joint Commission has required U.S. hospitals to provide nutrition screening to all patients within 24 hours of admission, but that doesn't cover patients in other settings, nor is there a standardized assessment tool for finding malnutrition in older adults. The Mini Nutritional Assessment is an effective, easily administered tool designed to identify older adults who have or are at risk for developing malnutrition. It consists of 18 questions and can be completed in about 15 minutes. A short form, containing the first six questions, can be used for screening. For a free online video demonstrating the use of this tool, go to http://links.lww.com/A221.

Intravenous ribavirin was provided non-selectively for investigational open-label use among persons with suspected hantavirus pulmonary syndrome (HPS) in the United States between 4 June 1993 and 1 September 1994. Therapy was initiated prior to laboratory confirmation of hantavirus infection because most deaths from HPS occur within 48 h of hospitalization. Thirty patients with confirmed HPS, 105 patients without HPS and 5 patients without adequate diagnostic testing for HPS were enrolled. This observational study arguably provides the most complete information available on ribavirin-associated adverse effects. Although ribavirin was generally well tolerated, 71% of recipients became anaemic and 19% underwent transfusion. An apparent excess of hyperamylasaemia/pancreatitis was either therapy-associated or due to enrollment bias. The 30 enrolled HPS patients had a case-fatality rate of 47% (14/30). It is not possible to assess efficacy with this study design. However, comparison of survival curves for the 30 enrolled HPS patients and 34 patients who developed HPS during the same time period but were not enrolled did not suggest an appreciable drug effect. A randomized, placebo-controlled trial that enrolls patients during the prodrome phase would be necessary to assess the efficacy and further define the safety of intravenous ribavirin for HPS.

The currently available, standard soybean oil (SO)-based intravenous fat emulsions (IVFEs) meet the needs of most parenteral nutrition (PN) patients. There are alternative oil-based fat emulsions, such as medium-chain triglycerides (MCTs), olive oils (OOs), and fish oils (FOs), that, based on extensive usage in Europe, have an equivalent safety profile to SO. These alternative IVFEs are metabolized via different pathways, which may lead to less proinflammatory effects and less immune suppression. These alternative oil-based IVFEs are not currently available in the United States. Many patients who require IVFEs are already in a compromised state. Such patients could potentially have better clinical outcomes when receiving one of the alternative IVFEs to diminish the intake of the potentially proinflammatory ω-6 fatty acid-linoleic acid-which comprises more than 50% of the fatty acid profile in SO. Further research is needed on these alternative oil-based IVFEs to identify which IVFE oils or which combination of oils may be most clinically useful for specific patient populations.

OBJECTIVES: The purpose of the present study was to evaluate the nutritional status of cancer patients receiving radiotherapy (RT) and to assess the possible contributions of nutritional support to patients with malnutrition. METHODS: Prospectively, 207 patients referred to our outpatient radiotherapy department were included. The patients were classified according to tumor site (head/neck, breast, lung, stomach, or colorectal). Nutritional status at the onset, at the end of RT, and 3 and 6 months after irradiation was evaluated with the subjective global assessment (SGA). All of the patients were supported with additional portions of meal or standard enteral feeding formula during and after the irradiation period as long as they were in the moderately or severely malnourished groups, respectively. RESULTS: At the onset, malnutrition was present in 31% of all patients, and it increased to 43% at the end of RT. This difference predominated in head/neck cancer patients. Malnutrition ratios in head/neck cancer patients at the onset and after RT were 24% and 88%, respectively. By a 6-month follow-up, the ratio of patients with malnutrition decreased to 8%. Nutritional status of all groups was found to improve during the 6-month follow-up period, except for the breast cancer group, which included no patients with severe malnutrition at any time. CONCLUSION: The results of the present study may be helpful in planning an appropriate nutritional support for cancer patients undergoing radiotherapy according to the irradiation site.

Abstract: At present there is no universally accepted classification for gastritis. The first successful classification (The Sydney System) that is still commonly used by medical professionals was first introduced by Misiewicz et al in Sydney in 1990. In fact, it was the first detailed classification after the discovery of Helicobacter pylori by Warren and Marshall in 1982. In 1994, the Updated Sydney System was proposed during the International Workshop on the Histopathology of Gastritis followed by the publication in The American Journal of Surgical Pathology by Dixon et al. Using the new classification, distinction between atrophic and nonatrophic gastritis was revised, and the visual scale grading was incorporated. According to the Updated Sydney System Classification, atrophic gastritis is categorized into multifocal ( H. pylori , environmental factors, specific diet) and corpus-predominant (autoimmune). Since metaplasia is a key histological characteristic in patients with atrophic gastritis, it has been recommended to use the word “metaplastic” in both variants of atrophic gastritis: autoimmune metaplastic atrophic gastritis (AMAG) and environmental metaplastic atrophic gastritis. Although there are many overlaps in the course of the disease and distinction between those two entities may be challenging, the aim of this review article was to describe the etiology, epidemiology, pathogenesis, diagnosis, clinical manifestations and treatment in patients with AMAG. However, it is important to mention that H. pylori is the most common etiologic factor for the development of gastritis in the world. Keywords: autoimmune gastritis, pernicious anemia, gastric carcinoid

BACKGROUND: Malnutrition risk estimates vary greatly, and no robust data on the association between food intake and outcomes exist for hospitals in the United States (U.S.). This study aimed to determine the prevalence of malnutrition risk and to evaluate the impact of food intake on mortality using the nutritionDay in the U.S. dataset. METHODS: This study analyzed data from 2009 to 2015 for all adult patients from participating hospitals. Prevalence of malnutrition risk was determined by mapping self-reported nutritionDay survey questions to the Malnutrition Screening Tool (MST). Fine and Gray competing-risk analysis with clustering was used to evaluate the impact of nutrition risk and food intake on patients' 30-day in-hospital mortality, while controlling for age, mobility, and other disease-related factors. RESULTS: Analysis included data from 9959 adult patients from 601 wards. The overall prevalence of malnutrition risk (MST score ≥2) was 32.7%. On nutritionDay, 32.1% of patients ate a quarter of their meal or less. Hospital mortality hazard ratio was 3.24 (95% CI: [1.73, 6.07]; P-value < 0.001) for patients eating a quarter compared with those who ate all their meal and increased to 5.99 (95% CI: [3.03, 11.84]; P-value < 0.0001) for patients eating nothing despite being allowed to eat. CONCLUSION: This study provides the most robust estimate of malnutrition risk in U.S. hospitalized patients to date, finding that approximately 1 in 3 are at risk. Additionally, patients who have diminished meal intake experience increased mortality risk. These results highlight the ongoing issue of malnutrition in the hospital setting.